Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma

Zi, Wu; Wang, Su Gui; Li, Qiang; Qing, Zhao; Shao, Ming

doi:10.3934/mbe.2020108

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,5 Previous studies reported that lncRNAs are dysregulated in different types of cancers and have critical effects related to cancer biology. [6][7][8][9] Some lncRNAs have been reported to be closely related to liver cancer pathology, progression, prognosis, and the maintenance of cancer stem celllike properties. 10,11 For example, LINC00668 up-regulation accelerates cell proliferation, migration, and invasion of HCC via targeting miR-532-5p/YY1 axis; 12 HAGLROS is highexpressed in HCC and its high expression is correlated with the progression of HCC by affecting cell proliferation, apoptosis, and autophagy via regulating miR-5095/ATG12 axis; 13 HCC patients with high-expressed lncRNA PDZD7 tend to show a poorer prognosis; PDZD7 promotes stemness properties and inhibits chemosensitivity of HCC via regulating the miR-101/EZH2/ATOH8 pathway.…”

Section: Introductionmentioning

confidence: 99%

<p>LncRNA CDKN2B-AS1 Promotes Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma via Sponging miR-424-5p</p>

Shen¹,

Yong²,

He³

et al. 2020

CMAR

View full text Add to dashboard Cite

Objective: Hepatocellular carcinoma (HCC) results in high mortality and metastasis. In this study, the effects of long non-coding RNA (lncRNA) CDKN2B-AS1 on the progression of HCC were investigated. Materials and Methods: LncRNA CDKN2B-AS1 expression of HCC cancer and adjacent tissues, and HCC cells were detected. Subsequently, CDKN2B-AS1 was overexpressed and silenced in HCC cells to observe the effects of CDKN2B-AS1 on the cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) of HCC cells by performing cell counting kit-8 (CCK-8), wound-healing, Transwell, and Western blot. The target gene of CDKN2B-AS1 was predicted and verified to be miR-424-5p, whose expression in HCC cells with up-or down-regulation of CDKN2B-AS1 expression was determined. Moreover, the effects of miR-424-5p on cell viability, migration, and invasion and EMT of HCC cells were investigated with miR-424-5p up-regulation or down-regulation, together with overexpression or silencing of CDKN2B-AS1. Results: CDKN2B-AS1 expression was increased in HCC tissues and cells. Silencing of CDKN2B-AS1 suppressed cell viability, migration, invasion, and EMT, while overexpression of CDKN2B-AS1 produced the opposite results. Furthermore, CDKN2B-AS1 was predicted and verified to target miR-424-5p and was confirmed to negatively modulate miR-424-5p expression. Moreover, overexpression of miR-424-5p partially suppressed the previously high cell viability, migration, and invasion, and activated EMT resulted from upregulation of CDKN2B-AS1, while silencing of miR-424-5p elevated the cellular processes inhibited by silencing the expression of CDKN2B-AS1. Conclusion: The present study revealed that high-expressed CDKN2B-AS1 may associate with the progression of HCC by affecting the cell viability, migration, invasion, and EMT of HCC cells by negatively regulating miR-424-5p.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>LncRNA CDKN2B-AS1 Promotes Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma via Sponging miR-424-5p</p>

Shen¹,

Yong²,

He³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma

Liang

Xia

Yao

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Four long noncoding RNAs act as biomarkers in lung adenocarcinoma

Zhang

Yang

et al. 2021

Open Medicine

View full text Add to dashboard Cite

Introduction Lung adenocarcinoma (LUAD) is currently one of the most common malignant tumors worldwide. However, there is a lack of long noncoding RNA (lncRNA)-based effective markers for predicting the prognosis of LUAD patients. We identified four lncRNAs that can effectively predict the prognosis of LUAD patients. Methods We used data gene expression profile for 446 patients from The Cancer Genome Atlas database. The patients were randomly divided into a training set and a test set. Significant lncRNAs were identified by univariate regression. Then, multivariate regression was used to identify lncRNAs significantly associated with the survival rate. We constructed four-lncRNA risk formulas for LUAD patients and divided patients into high-risk and low-risk groups. Identified lncRNAs subsequently verified in the test set, and the clinical independence of the lncRNA model was evaluated by stratified analysis. Then mutated genes were identified in the high-risk and low-risk groups. Enrichment analysis was used to determine the relationships between lncRNAs and co-expressed genes. Finally, the accuracy of the model was verified using external database. Results A four-lncRNA signature (AC018629.1, AC122134.1, AC119424.1, and AL138789.1) has been verified in the training and test sets to be significantly associated with the overall survival of LUAD patients. Conclusions The present study demonstrated that identified four-lncRNA signature can be used as an independent prognostic biomarker for the prediction of survival of LUAD patients.

show abstract

Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma

Cited by 4 publications

References 19 publications

<p>LncRNA CDKN2B-AS1 Promotes Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma via Sponging miR-424-5p</p>

<p>LncRNA CDKN2B-AS1 Promotes Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma via Sponging miR-424-5p</p>

Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma

Four long noncoding RNAs act as biomarkers in lung adenocarcinoma

Contact Info

Product

Resources

About